Samsung Bioepis partners with C-Bridge Capital to expand biosimilar portfolio in China

Samsung Bioepis, a South Korean leader in biopharmaceuticals, has struck a deal with private equity firm C-Bridge Capital to develop and commercialize next-generation biosimilars in ... Read More